A randomized clinical trial of an NAD+ precursor in Parkinson's disease did not produce the expected slowing of clinical progression, despite strong preclinical and mechanistic rationale for restoring cellular NAD+ levels in dopaminergic neurons. Raising a metabolite's availability does not guarantee that it is routed to the compartments or pathways where deficiency causes harm. The result tempers expectations for NAD+ repletion as a disease-modifying strategy in established neurodegeneration.
Key Points
- NAD+ precursor supplementation did not slow Parkinson's disease progression in trial
- Preclinical mitochondrial rationale failed to translate into clinical benefit
- Raising systemic NAD+ may not reach affected neuronal compartments
Longevity Analysis
NAD+ repletion has become one of the most widely adopted interventions in consumer longevity practice, largely on the strength of mechanistic plausibility and animal data rather than hard clinical endpoints. A negative result in a neurodegenerative population clarifies the limits of supplying a substrate when the underlying failure may lie in how cells consume, compartmentalize, or regulate it — the energy-generating machinery of neurons is governed by more than precursor availability. The practical implication is to interpret biochemical markers in context rather than treating a measurable rise in a metabolite as evidence of functional benefit, and to weight interventions by the outcomes they have actually moved.
Original published by Nature Aging, by Michael Attwaters.